Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: A Post-marketing Surveillance Study of 3085 Patients†

Narikazu Boku1,*, Kenichi Sugihara2, Yuko Kitagawa3, Kiyohiko Hatake4, Akihiko Gemma5, Naoya Yamazaki6, Kei Muro7, Tetsuya Hamaguchi8, Takayuki Yoshino9, Ikuyo Yana10, Hiroshi Ueno11 and Atsushi Ohtsu12

1Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, 2Department of Surgical Oncology, Tokyo Medical and Dental University, Graduate School, Tokyo, 3Department of Surgery, Keio University School of Medicine, Tokyo, 4Department of Medical Oncology/Hematology of Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, 5Division of Pulmonary Medicine, Infectious Diseases and Oncology, Nippon Medical School, Tokyo, 6Dermatologic Oncology Division, National Cancer Center Hospital, Tokyo, 7Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, 8Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, 9Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, 10Takeda Bio Development Center Limited, Tokyo, 11Takeda Pharmaceutical Company Limited, Osaka, and 12Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Japan

*For reprints and all correspondence: Narikazu Boku, Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki 216-8511, Japan. E-mail: n.boku@marianna-u.ac.jp

†Presented, in part, at the 37th European Society for Medical Oncology (ESMO) Congress, 28 September–2 October 2012, Vienna, Austria, and the ASCO Gastrointestinal Cancers Symposium, 24–26 January 2013, San Francisco, USA.

Received September 3, 2013; accepted November 17, 2013

Objective: Panitumumab was approved in Japan in April 2010 for the treatment of Kirsten rat sarcoma-2 virus oncogene wild-type unresectable and recurrent colorectal cancer. We conducted a post-marketing surveillance study to evaluate the safety and effectiveness of panitumumab.

Methods: After panitumumab was commercially available in Japan, all patients to be treated with panitumumab were enrolled. Data on baseline characteristics, treatment outcome, and incidence and severity of adverse drug reactions were collected.

Results: In total, 3091 patients were registered. In the safety analysis set (n = 3085), panitumumab was administered as monotherapy (40.7%) or combination therapy (59.4%). The median treatment duration was 113 days (range: 1–559 days), and 451 (14.6%) patients received panitumumab for ≥10 months. The overall incidence rate of adverse drug reactions was 84.1%, and the most common adverse drug reaction was skin disorders (78.4%). The incidence rates (all grades) of interstitial lung disease, infusion reaction, electrolyte abnormalities and cardiac disorders were 1.3% (mortality rate: 0.6%), 1.5, 19.3 and 0.2%, respectively. The median survival time of patients treated with panitumumab monotherapy as the third-line, or later, therapy was 10.3 months.

Conclusion: This post-marketing survey in clinical practice confirmed the safety and effectiveness of panitumumab. The benefit/risk balance for panitumumab in Japanese patients with unresectable colorectal cancer remains favorable.

Key words: colorectal cancer – panitumumab – post-marketing surveillance – safety
INTRODUCTION

Colorectal cancer is one of the most common cancers, representing the second (males; 9%) and third (females; 8%) most prevalent cancer in the USA (1), and the third overall leading cause of cancer-related death in the Western world (2). The past several decades have seen a dramatic increase in the incidence of colorectal cancer also in Japan (3); in 2008, age-standardized incidence rates in males and females in Japan were 41.7 and 22.8 cases per 100,000, with corresponding death rates of 15.2 and 8.9 per 100,000, respectively (4).

The introduction of monoclonal antibody-based therapy targeting epidermal growth factor receptor (EGFR) has provided new alternative treatment options for various types of malignancy, including colorectal cancer (5–8).

Panitumumab is a high-affinity, fully human IgG2 monoclonal antibody specific to the extracellular domain of EGFR (5,9). The clinical efficacy and tolerability of panitumumab have been well established in large, randomized, controlled clinical trials as monotherapy (10–13) or in combination with cytotoxic agents (14–17), in the first-, second- and third-line, or later, settings for patients with unresectable, advanced or recurrent colorectal cancer with wild-type Kirsten rat sarcoma-2 virus oncogene (KRAS). Panitumumab was first approved in the USA (September 2006) and European Union (EU) (December 2007) as monotherapy and for use in combination therapy in the EU (November 2011).

In Japan, panitumumab was approved (April 2010) for the treatment of wild-type KRAS gene unresectable, advanced and recurrent colorectal cancer as monotherapy, and for use in combination therapy in the first-, second- and third-line, or later, settings based on global clinical trials (10–12,14–17). The approval of panitumumab in Japan for use in combination therapy represents the first such approval in the world. However, because the number of Japanese individuals enrolled in the global clinical trials was relatively limited (13), the Japanese Ministry of Health, Labour and Welfare required the market authorization holders to conduct a post-marketing surveillance study, called All Cases Surveillance (18), as a condition of its approval to evaluate the safety and effectiveness of all Japanese patients treated with panitumumab. The main purpose of this study was to collect detailed information, particularly with regard to safety issues, on all panitumumab-treated patients; additionally, by evaluating a large number of patients, the study aimed to identify rare adverse drug reactions (ADRs), which are often undetectable in smaller clinical trials. The current paper reports the findings of the Japanese all cases surveillance study.

PATIENTS AND METHODS

This post-marketing surveillance study was planned to include all patients treated with panitumumab from the start date (15 June 2010) of its launch in Japan. To promote the appropriate use and evaluate safety information, a Vectibix Appropriate Use Committee, a Vectibix Safety Evaluation Committee and a Vectibix Interstitial Lung Disease (ILD) review subcommittee were organized. All reported ILD-like events were assessed individually by an ILD review subcommittee, comprising external experts in the field of radiology, pulmonology and medical oncology. Evaluation of ILD-like events was performed using computed tomography (CT) and X-ray imaging, and by assessment of clinical information. Completion of a specific registration form (Fig. 1), which reported patient characteristics and treatment information, was mandatory before panitumumab treatment was initiated. The registration period of this post-marketing surveillance was June 2010 to November 2010. Patients were carefully observed, and information during their clinical courses for 10 months (42 weeks), or until discontinuation of panitumumab for any reason, was collected through the pre-specified case report forms (CRFs). At the time of registration, a recommendation letter to stop initiating treatment with panitumumab was sent from the Vectibix Appropriate Use Committee to each attending doctor if at least one item on the dark gray zone of the registration form was checked (Fig. 1).

Subsequently, the following information relating to clinical course was collected using CRFs: (1) patient background including prior chemotherapy and reason for its discontinuation/termination; (2) administration of panitumumab including its dose and date, premedication to prevent infusion reaction, concurrent medications and combined therapy; (3) laboratory tests including serum magnesium, calcium and potassium; (4) adverse events including time to onset, grade according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) ver. 4.0, treatment, causality of panitumumab and recovery and (5) outcomes including disease progression, survival or death.

An ADR was defined as an adverse event for which a causal relationship with panitumumab could not be ruled out. ADRs were coded using Medical Dictionary for Regulatory Activities (MedDRA) version 15.0. With regard to toxicity, skin disorders, ILD, infusion reaction, electrolyte abnormalities and cardiac disorders were monitored with special interest. The effectiveness of panitumumab was assessed by overall survival, calculated using the Kaplan–Meier method. Overall survival time was defined as the time from the date of first administration of panitumumab to the date of death (regardless of the cause of death) or censored on the last date of survival (date of confirmation of survival as recorded in the CRF or, if there was no information regarding the date of confirmation of survival, the last date of panitumumab administration was used for calculation purposes).

This survey was initiated in June 2010 and the data lock point of the final analysis was set at 12 September 2012.

RESULTS

PATIENT CHARACTERISTICS

During the registration period from June to November 2010, a total of 3091 patients were registered (completion of
Table 1 shows the clinical background of the 3085 patients at registration. While a KRAS test was attempted for all registered patients, it was not determined for 79 patients (2.6%) mainly due to the condition of the tissues. Despite a recommendation letter to stop, panitumumab was administered to three patients (0.1%) with mutant KRAS at each physician’s discretion. The majority of patients (91.4%) had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–1. Although the ECOG PS of 3080 patients was reported to be 0–2 at registration, 5 patients with PS 3 were registered despite requests for reassessment of administration. The general condition of 20 patients deteriorated to PS 3 or 4 before the administration of panitumumab. Therefore, patients with PS 3 (0.7%) or 4 (0.1%) were included in this surveillance. There were no other registered patients who met at least one item in the dark gray zone of the registration form (Fig. 1).

Panitumumab was used in the third-line, or later, setting for metastatic disease in 72.4% of patients, and previous anticancer treatment including adjuvant chemotherapy had been administered to 94.4% of patients, such as FOLFOX (79.1%), FOLFIRI (61.8%) and bevacizumab (monoclonal antibody, vascular endothelial growth factor-specific angiogenesis inhibitor; 68.5%); 29.7% of patients had received cetuximab (monoclonal antibody, EGFR antagonist) (duplicate counting).

Figure 3 shows treatment regimens administered and the status of administration (safety analysis set). At the start of panitumumab administration, 1254 (40.7%) patients received monotherapy and 1831 (59.4%) patients received combination chemotherapy. Combination therapy consisted (duplicate counting) of FOLFOX4 (3.6%), mFOLFOX6 (15.1%), FOLFIRI (33.9%), 5FU/l-LV (2.0%), CPT-11 (9.0%), S-1 + CPT-11 (1.3%) or other chemotherapy (3.1%). Of the 310 patients receiving first-line treatment, the majority (86.5%) received combination therapy, of which 193 patients received concomitant FOLFOX (62.3%). With regard to the use of panitumumab monotherapy in the first-line setting, primary physicians did not select combination chemotherapy considering

---

| History of severe hypersensitivity to the ingredients* of this drug. | No | Yes |
|---|---|---|

*Panitumumab, sodium chloride and sodium acetate.

| Primary tumor | Colon/rectum (including RS) | Other ( ) |
|---|---|---|

| Purpose | Treatment of unresectable, advanced/recurrent cancer | Post-operative adjuvant therapy | Other ( ) |
|---|---|---|

| KRAS genotype | Wild | Not determinable | Mutant | Not measured |
|---|---|---|---|---|

| Treatment stage (excluding post-operative adjuvant therapy) | First line | Second line | Third line or later |
|---|---|---|---|

| ECOG PS score | 0 | 1 | 2 | 3 | 4 |
|---|---|---|---|---|---|

| History of or complication with interstitial pneumonia/pulmonary fibrosis | None | Interstitial pneumonia ( Complication; History) | Pulmonary fibrosis ( Complication; History) |
|---|---|---|---|

| Pregnancy/lactation status (for female patients) | None | Pregnant | Lactating |
|---|---|---|---|

| Concomitant chemotherapy planned | Yes → FOLFOX | No → FOLFIRI | Chemotherapy other than FOLFOX and FOLFIRI |
|---|---|---|---|

If one or more boxes in the gray-shaded cells are checked, avoidance of administration is requested by the Takeda/Vectibix Appropriate Use Committee. If one or more boxes in the light gray-shaded cells (framed from a dark-black line) are marked, reassessment of administration is requested by the Takeda/Vectibix Appropriate Use Committee.

Figure 1. Patient registration form—excerpt.
various patient factors, such as age and general condition, because there is no limitation in the indication of panitumumab for combination or monotherapy in Japan. Combination therapy was administered in 394 of 543 (72.6%) patients as second-line treatment, of whom 276 (50.8%) received FOLFIRI. Almost half (47.6%) of the 2232 patients receiving third-line, or later, treatment were in the monotherapy group.

TREATMENT COURSE
The median period of treatment with panitumumab was 113.0 days (range: 1–559 days), with 14.6% of patients receiving panitumumab for >10 months.

Panitumumab was discontinued in 2592 (84.0%) patients in the safety analysis set (n = 3085). The main reasons for discontinuation (with some duplicate counting) were as follows: disease progression in 1903 (61.7%) patients, of which 1484 patients (78.0%) had confirmed disease progression by diagnostic imaging; occurrence of adverse events in 431 (14.0%) patients; patient refusal (190 patients; 6.2%); lack of patient hospital visits (30 patients; 1.0%) and other reasons (185 patients; 6.0%).

SAFETY ANALYSIS
The overall incidence of ADRs in all grades was 84.1% (2595/3085 patients) (Table 2). The most common classification, according to the MedDRA system organ class (SOC), was ‘skin and subcutaneous tissue disorders’ (76.6%; 2364/3085) (Table 2), followed by ‘infections and infestations’ [(25.0%; 771/3085), which included paronychia (23.7%; 731/3085)], ‘gastrointestinal disorders’ (20.8%; 642/3085) and ‘metabolism and nutrition disorders’ (17.9%; 552/3085).

The incidence of ADRs in the monotherapy group (n = 1254) was 80.1% (1004/1254); 19.7% of these were ≥Grade 3 and 5.4% were classified as serious cases. In patients receiving combination therapy (n = 1831), 86.9% reported ADRs; 30.0% of these were ≥Grade 3 and 7.9% were serious cases. There were no major differences in the incidence of ADRs by combined regimens in the combination therapy group: FOLFOX (overall: 86.7%, ≥Grade 3: 29.3% and serious cases: 9.1%) and FOLFIRI (87.4, 29.8 and 8.1%, respectively).

A summary of safety data from the post-marketing surveillance study and panitumumab clinical trials (19) is presented in Table 3.

SKIN DISORDERS
The overall incidence rate of ‘major skin disorders’ (which includes all related events) was 78.4% (≥Grade 3, 14.7%). Dermatitis acneiform occurred in 69.9% of patients (≥Grade 3, 10.5%), paronychia in 24.2% (≥Grade 3, 4.3%), dry skin in 21.7% (≥Grade 3, 2.1%) and pruritus in 4.8% (≥Grade 3,
The median time from the first day of treatment to the onset of each of the major skin disorders was as follows: 15 days for dermatitis acneiform, 43 days for paronychia, 29 days for dry skin and 21 days for pruritus. Major skin disorders caused discontinuation of panitumumab in 7.0% (168/2419) of patients. The prevalence of skin disorders was similar with panitumumab monotherapy (74.7%; 937/1254) and panitumumab plus chemotherapy (80.9%; 1482/1831).

**ELECTROLYTE ABNORMALITIES**

Serum magnesium, calcium and potassium were checked at least once during treatment in 46.2% (1425/3085), 65.4% (2016/3085) and 92.5% (2855/3085) of the patients, respectively. The incidence rate of electrolyte abnormalities was 19.3% (596/3085), with that of Grade 3 cases being 4.8% (149/3085). The respective incidence rates of hypomagnesemia, hypocalcemia and hypokalemia in patients for whom laboratory data for these three electrolytes were available were 36.5% (520/1425), 6.7% (136/2016) and 2.3% (67/2855). The incidence rate of hypomagnesemia in the overall population was 16.9% (520/3085), with that of Grade 3 hypomagnesemia being 4.0% (123/3085). The median time to hypomagnesemia onset after panitumumab treatment initiation was 63 days in all cases: 39.5 days in patients who were treated with cetuximab immediately before panitumumab and 71 days in patients who were not. The incidence of hypomagnesemia and hypocalcemia peaked at 3–4 months after the start of panitumumab administration. Patients with low serum magnesium values also tended to have low serum calcium values.

Of 105 patients who experienced both hypomagnesemia and hypocalcemia, 42 patients had the same grade of hypomagnesemia and hypocalcemia; 42 and 21 patients compared to each other had higher grades of hypomagnesemia and hypocalcemia, respectively. Of 30 patients with Grade 3 hypomagnesemia and hypocalcemia, 5 patients experienced relevant clinical symptoms accompanying electrolyte abnormalities: QTc prolongation (3 cases), rhabdomyolysis, paralysis, tetany and convulsion (1 case of each).

**INFUSION REACTION**

Infusion reaction occurred in 1.5% (47/3085) of patients, with an incidence rate of Grade 3 or serious cases of 0.2% (6/3085). No Grade 4 cases, or deaths due to infusion reaction, were reported. Infusion reaction occurred at initial administration in 61.7% (29/47) of patients and in 14.9% (7/47) of patients at second administration, while the first infusion reaction occurred at the time of the third or later administration in the remaining 11 patients (with the latest infusion reaction occurring at the 21st administration). Panitumumab was administered to 70 patients who had past histories of infusion reaction due to cetuximab, following premedication and at reduced speed of infusion in almost all cases. Two of these patients (2.9%) experienced Grade 1 infusion reaction, while infusion reaction occurred in 9/847 (1.1%) patients without a history of infusion reaction to cetuximab administration.

---

**Table 1. Patient demographics and baseline characteristics**

| Baseline characteristic | Number | % |
|-------------------------|--------|---|
| Gender                  |        |   |
| Male                    | 1965   | 63.7 |
| Female                  | 1120   | 36.3 |
| Age (years)             |        |   |
| <65                     | 1524   | 49.4 |
| 65–74                   | 1058   | 34.3 |
| ≥75                     | 503    | 16.3 |
| Median (range) (years)  | 65.0 (18–90) |   |
| KRAS status             |        |   |
| Wild                    | 3003   | 97.3 |
| Mutant                  | 3      | 0.1 |
| Not determinable        | 79     | 2.6 |
| Primary tumor type (duplicate counting) | | |
| Colon                   | 1860   | 60.3 |
| Resected                | 1621   | 52.5 |
| Unresected              | 239    | 7.8 |
| Rectal                  | 1244   | 40.3 |
| Resected                | 1054   | 34.2 |
| Unresected              | 189    | 6.1 |
| Colorectal              | 3085   | 100.0 |
| Resected                | 2661   | 86.3 |
| Unresected              | 423    | 13.7 |
| Treatment line          |        |   |
| First-line              | 310    | 10.1 |
| Second-line             | 543    | 17.6 |
| Third-line or later     | 2232   | 72.4 |
| ECOG performance status |        |   |
| 0                       | 1877   | 60.9 |
| 1                       | 942    | 30.5 |
| 2                       | 241    | 7.8 |
| 3                       | 22     | 0.7 |
| 4                       | 3      | 0.1 |
| Past treatment regimens |        |   |
| No                      | 173    | 5.6 |
| Yes (duplicate counting)| 2911   | 94.4 |
| FOLFOX                  | 2439   | 79.1 |
| FOLFIRI                 | 1907   | 61.8 |
| Bevacizumab             | 2113   | 68.5 |
| Cetuximab               | 917    | 29.7 |

**KRAS**, Kirsten rat sarcoma-2 virus oncogene; **ECOG**, Eastern Cooperative Oncology Group; **FOLFOX**, 5-fluorouracil, leucovorin, oxaliplatin; **FOLFIRI**, 5-fluorouracil, leucovorin, irinotecan.

*Mainly due to the condition of tissue samples; reasonable attempts were made to determine the **KRAS** status for all patients.

*Treatment for metastatic or recurrent disease, excluding postoperative adjuvant chemotherapy from counting treatment lines.

*Specified PS immediately before panitumumab administration. Although 3080 patients were reported to be PS 0–2, the general condition worsened to PS 3 in 17 patients and to PS 4 in 3 patients.
INTERSTITIAL LUNG DISEASE

Overall, the incidence rate of ILD was 1.3% (39/3085): 1.3% in monotherapy and 1.3% in combination therapy, resulting in a mortality rate of 0.6% (20/3085). Of the total ILD cases, 51.3% (20/39) were fatal. The time to onset of ILD varied (Table 4). As determined by CT imaging, diffuse alveolar damage (DAD) was observed in 46.2% (18/39) of patients and 15 of the 18 DAD cases were fatal. The remaining ILD cases were diagnosed as hypersensitivity pneumonia (9 cases) or organizing pneumonia (8 cases), with 4 unevaluable cases.

CARDIAC DISORDERS

The incidence of cardiac disorders was 0.2% (7/3085), with death due to heart failure (Grade 5) reported in one patient. In this patient, treated with panitumumab and FOLFIRI, pancytopenia (not related to panitumumab) appeared on Day 23, followed by pneumonia (Day 28) and heart failure (Day 32).

CASES OF DEATH

In total, 1135 deaths were recorded, and most of them were related to progression of colorectal cancer. However, in 25 (2.2%) patients, a relationship to panitumumab treatment could not be ruled out. Among these, the most common cause of death was ILD (20 patients, according to the evaluation of the ILD subcommittee).

EFFECTIVENESS

Figure 4 shows the Kaplan–Meier curve for overall survival based on 1062 patients in the safety analysis set who were receiving panitumumab monotherapy in the third-line, or later, setting.

The median overall survival time (95% confidence interval) was $\sim 10.3$ months ($\sim 9.0–11.8$ months), with 56.6% censored cases.

DISCUSSION

The main objective of the current post-marketing surveillance study was to evaluate the safety of panitumumab in Japanese patients with unresectable colorectal cancer (and with the majority of patients possessing wild-type KRAS tumors) in clinical practice.
The overall incidence of ADRs was 84.1%, with skin disorders representing the most common classification (78.4%). Skin toxicity associated with panitumumab (and other EGFR antibodies) is well known (20). Indeed, the development of skin disorders, particularly rash, is considered to be a predictive factor for the efficacy of EGFR inhibitors (21,22). As reported previously with EGFR inhibitors (22,23), dermatitis acneiform (69.9%) was the most frequent skin disorder reported in the current study, occurring about 2 weeks after the initiation of panitumumab. In the current study, although major skin disorders such as dermatitis acneiform, paronychia, dry skin and pruritus occurred in 78.4% of patients, 93% of the patients who experienced skin disorders were able to continue panitumumab therapy.

The EGFR-signaling pathway potentially plays a pivotal role in regulating magnesium homeostasis, and, indeed, hypomagnesemia/magnesium has been shown in patients with colorectal cancer receiving EGFR-targeting antibodies (24). In the current study, 46.2% of patients were evaluated for serum magnesium, and Grade 3 or higher hypomagnesemia occurred in 78.4% of patients, 93% of the patients who experienced skin disorders were able to continue panitumumab therapy.

The overall incidence of ADRs was 84.1%, with skin disorders representing the most common classification (78.4%). Skin toxicity associated with panitumumab (and other EGFR antibodies) is well known (20). Indeed, the development of skin disorders, particularly rash, is considered to be a predictive factor for the efficacy of EGFR inhibitors (21,22). As reported previously with EGFR inhibitors (22,23), dermatitis acneiform (69.9%) was the most frequent skin disorder reported in the current study, occurring about 2 weeks after the initiation of panitumumab. In the current study, although major skin disorders such as dermatitis acneiform, paronychia, dry skin and pruritus occurred in 78.4% of patients, 93% of the patients who experienced skin disorders were able to continue panitumumab therapy.

The EGFR-signaling pathway potentially plays a pivotal role in regulating magnesium homeostasis, and, indeed, hypomagnesemia/magnesium has been shown in patients with colorectal cancer receiving EGFR-targeting antibodies (24). In the current study, 46.2% of patients were evaluated for serum magnesium, and Grade 3 or higher hypomagnesemia occurred in 78.4% of patients, 93% of the patients who experienced skin disorders were able to continue panitumumab therapy.

The overall incidence of ADRs was 84.1%, with skin disorders representing the most common classification (78.4%). Skin toxicity associated with panitumumab (and other EGFR antibodies) is well known (20). Indeed, the development of skin disorders, particularly rash, is considered to be a predictive factor for the efficacy of EGFR inhibitors (21,22). As reported previously with EGFR inhibitors (22,23), dermatitis acneiform (69.9%) was the most frequent skin disorder reported in the current study, occurring about 2 weeks after the initiation of panitumumab. In the current study, although major skin disorders such as dermatitis acneiform, paronychia, dry skin and pruritus occurred in 78.4% of patients, 93% of the patients who experienced skin disorders were able to continue panitumumab therapy.

The overall incidence of ADRs was 84.1%, with skin disorders representing the most common classification (78.4%). Skin toxicity associated with panitumumab (and other EGFR antibodies) is well known (20). Indeed, the development of skin disorders, particularly rash, is considered to be a predictive factor for the efficacy of EGFR inhibitors (21,22). As reported previously with EGFR inhibitors (22,23), dermatitis acneiform (69.9%) was the most frequent skin disorder reported in the current study, occurring about 2 weeks after the initiation of panitumumab. In the current study, although major skin disorders such as dermatitis acneiform, paronychia, dry skin and pruritus occurred in 78.4% of patients, 93% of the patients who experienced skin disorders were able to continue panitumumab therapy.

The overall incidence of ADRs was 84.1%, with skin disorders representing the most common classification (78.4%). Skin toxicity associated with panitumumab (and other EGFR antibodies) is well known (20). Indeed, the development of skin disorders, particularly rash, is considered to be a predictive factor for the efficacy of EGFR inhibitors (21,22). As reported previously with EGFR inhibitors (22,23), dermatitis acneiform (69.9%) was the most frequent skin disorder reported in the current study, occurring about 2 weeks after the initiation of panitumumab. In the current study, although major skin disorders such as dermatitis acneiform, paronychia, dry skin and pruritus occurred in 78.4% of patients, 93% of the patients who experienced skin disorders were able to continue panitumumab therapy.

The overall incidence of ADRs was 84.1%, with skin disorders representing the most common classification (78.4%). Skin toxicity associated with panitumumab (and other EGFR antibodies) is well known (20). Indeed, the development of skin disorders, particularly rash, is considered to be a predictive factor for the efficacy of EGFR inhibitors (21,22). As reported previously with EGFR inhibitors (22,23), dermatitis acneiform (69.9%) was the most frequent skin disorder reported in the current study, occurring about 2 weeks after the initiation of panitumumab. In the current study, although major skin disorders such as dermatitis acneiform, paronychia, dry skin and pruritus occurred in 78.4% of patients, 93% of the patients who experienced skin disorders were able to continue panitumumab therapy.

The overall incidence of ADRs was 84.1%, with skin disorders representing the most common classification (78.4%). Skin toxicity associated with panitumumab (and other EGFR antibodies) is well known (20). Indeed, the development of skin disorders, particularly rash, is considered to be a predictive factor for the efficacy of EGFR inhibitors (21,22). As reported previously with EGFR inhibitors (22,23), dermatitis acneiform (69.9%) was the most frequent skin disorder reported in the current study, occurring about 2 weeks after the initiation of panitumumab. In the current study, although major skin disorders such as dermatitis acneiform, paronychia, dry skin and pruritus occurred in 78.4% of patients, 93% of the patients who experienced skin disorders were able to continue panitumumab therapy.

The overall incidence of ADRs was 84.1%, with skin disorders representing the most common classification (78.4%). Skin toxicity associated with panitumumab (and other EGFR antibodies) is well known (20). Indeed, the development of skin disorders, particularly rash, is considered to be a predictive factor for the efficacy of EGFR inhibitors (21,22). As reported previously with EGFR inhibitors (22,23), dermatitis acneiform (69.9%) was the most frequent skin disorder reported in the current study, occurring about 2 weeks after the initiation of panitumumab. In the current study, although major skin disorders such as dermatitis acneiform, paronychia, dry skin and pruritus occurred in 78.4% of patients, 93% of the patients who experienced skin disorders were able to continue panitumumab therapy.
In the current post-marketing surveillance study of panitumumab, the overall incidence rate of ILD was 1.3%, with a mortality rate of 0.6%. The incidence of ILD was similar to that reported in a post-marketing survey of cetuximab in Japan (1.2%) (23). The ILD subcommittee carried out a full evaluation of ILD with panitumumab, concluding that the onset of ILD can occur at any time after the start of panitumumab administration and that there were no findings specific to panitumumab, either clinically or in CT imaging. The DAD type of ILD occurred in some cases, as with cetuximab and the EGFR tyrosine kinase inhibitors gefitinib and erlotinib, and may be fatal. At present, no major differences in the incidence of ILD or in the rate of death due to ILD were found in comparison with cetuximab (23). Thus, ILD is one of the particular concerns with the use of panitumumab as well as other anti-EGFR drugs.

With regard to all panitumumab-related ADRs, there were no differences between its use as monotherapy or in combination therapy with cytotoxic agents, and the profile, incidences, onset and outcomes of these ADRs were very similar to those reported in previous clinical trials.

In contrast to the combination setting with chemotherapy regimens, the monotherapy setting represents the efficacy of panitumumab in clinical practice more accurately; therefore, patients treated with panitumumab monotherapy as a third-line or later therapy were selected for analysis of the effectiveness of panitumumab. The effectiveness of panitumumab, reported previously in clinical trials, was also confirmed in the current study.

Table 3. Summary of safety data

| Post-marketing survey in Japan | P-mab monotherapy (n = 1254) | Combination therapy (n = 1831) |
|--------------------------------|-----------------------------|------------------------------|
| ADRs of special interest       | All                         | ≥ Grade 3                    | All                         | ≥ Grade 3 |
|--------------------------------|------------------------------|------------------------------|------------------------------|----------|
| Skin disorders (SOC)           | 918                          | 118                          | 1446                         | 274      |
| Paronychia                     | 272                          | 33                           | 459                          | 99       |
| Interstitial lung disease*     | 16                           | —                            | 23                           | —        |
| Infusion reaction              | 17                           | 1                            | 17                           | 30       |
| Hypomagnesemia                 | 257                          | 61                           | 263                          | 62       |
| Hypocalcemia                   | 59                           | 16                           | 77                           | 26       |
| Cardiac disorders (SOC)        | 2                            | 0                            | 5                            | 1        |

Clinical trials<sup>c</sup>

| P-mab monotherapy<sup>d</sup> (n = 1052: KRAS WT) | P-mab + FOLFOX<sup>e</sup> (n = 322: KRAS WT) | P-mab + FOLFIRI<sup>f</sup> (n = 302: KRAS WT) |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| ADRs of special interest                      | All                                           | ≥ Grade 3                                    | All                                           | ≥ Grade 3 |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|----------|
| Skin disorders (SOC)                          | 969                                          | 130                                          | 308                                          | 110      |
| Paronychia                                     | 214                                          | 12                                           | 63                                           | 11       |
| Interstitial lung disease                      | 0                                            | 0                                            | 2                                            | 2        |
| Infusion reaction                              | 35                                           | 5                                            | 24                                           | 8        |
| Hypomagnesemia                                 | 79                                           | 22                                           | 89                                           | 19       |
| Hypocalcemia                                   | 11                                           | 5                                            | 14                                           | 3        |
| Cardiac disorders (SOC)                        | 10                                           | 3                                            | 7                                            | 3        |

P-mab, panitumumab.

<sup>a</sup>Based on the evaluation of the ILD review subcommittee.

<sup>b</sup>Including Grade-2 serious cases.

<sup>c</sup>Trial Nos: 20050216, 20040192, 20020408, 20030194, 20030167, 20030250, 20025405, 20030138, 20040116, 20030251, 20020375.

<sup>d</sup>Trial No: 2005203.

<sup>e</sup>Trial No: 2005181.

Table 4. Time to onset of interstitial lung disease (ILD)

| Time (months) | All |
|---------------|-----|
| ≤ 1           | 8   |
| 2             | 4   |
| 3             | 11  |
| 4             | 1   |
| 5             | 5   |
| 6             | 0   |
| 7             | 2   |
| 8             | 0   |
| 9             | 1   |
| 10            | 39  |

ILD cases: 8, 4, 11, 1, 4, 5, 0, 3, 2, 0, 1, 39

Fatal cases: (6) (2) (4) (0) (2) (2) (0) (1) (2) (0) (1) (20)

(Fig. 1). In the current post-marketing surveillance study of panitumumab, the overall incidence rate of ILD was 1.3%, with a mortality rate of 0.6%. The incidence of ILD was similar to that reported in a post-marketing survey of cetuximab in Japan (1.2%) (23). The ILD subcommittee carried out a full evaluation of ILD with panitumumab, concluding that the onset of ILD can occur at any time after the start of panitumumab administration and that there were no findings specific to panitumumab, either clinically or in CT imaging. The DAD type of ILD occurred in some cases, as with cetuximab and the EGFR tyrosine kinase inhibitors gefitinib and erlotinib, and may be fatal. At present, no major differences in the incidence of ILD or in the rate of death due to ILD were found in comparison with cetuximab (23). Thus, ILD is one of the particular concerns with the use of panitumumab as well as other anti-EGFR drugs.

With regard to all panitumumab-related ADRs, there were no differences between its use as monotherapy or in combination therapy with cytotoxic agents, and the profile, incidences, onset and outcomes of these ADRs were very similar to those reported in previous clinical trials.

In contrast to the combination setting with chemotherapy regimens, the monotherapy setting represents the efficacy of panitumumab in clinical practice more accurately; therefore, patients treated with panitumumab monotherapy as a third-line or later therapy were selected for analysis of the effectiveness of panitumumab. The effectiveness of panitumumab, reported previously in clinical trials, was also confirmed in the current study.
post-marketing surveillance study. In a pivotal, Phase III, randomized, controlled study (15), the median overall survival time in the panitumumab group (wild-type KRAS) was $\approx 8.1$ months ($\approx 6.3–9.4$ months) (11); data obtained from the present surveillance study exhibit a median overall survival of 10.3 months (56.6% censored cases).

Whilst acknowledging that post-marketing surveillance studies have some inevitable limitations (e.g. the lack of a control group) that differ from those in well-controlled, prospective clinical trials, it is recognized that post-marketing surveillance studies provide a information based on the general population (33). These factors result in greater external validity for post-marketing surveillance studies compared with well-controlled, randomized clinical trials (33). Despite these limitations, this large-scale, non-interventional study has some advantages. All patients treated with panitumumab were required to register before administration. Therefore, this surveillance study has minimum selection bias. This study also provides health-care professionals with valuable information on the safety and effectiveness of panitumumab based on real-world data.

In conclusion, the current post-marketing surveillance study in Japanese patients with unresectable colorectal cancer confirmed the safety profile and effectiveness of panitumumab that has been reported previously in clinical trials. No new safety signals were reported. It is considered that the benefit/risk balance for the use of panitumumab in patients with unresectable colorectal cancer remains favorable also in Japan.

Acknowledgements

The authors would like to thank all the patients and their families, investigators, medical staff and Vectibix ILD review subcommittee members (Shoji Kudoh, Fumikazu Sakai and Masahiro Endo). The authors thank David P. Figgitt, Content Ed Net, for providing valuable editorial assistance in the preparation of the manuscript. Editorial assistance was funded by Takeda Pharmaceutical Company Limited, Osaka, Japan. The authors would like to acknowledge Kouji Miyata, PMS study manager; and Miyo Yoneoka and Yumiko Ogino, Pharmacovigilance scientists (Takeda Pharmaceutical Co., Ltd); and the study team for their important contributions to the study. The authors wish to acknowledge the significant contribution to this study of the late Professor Hiroya Takiuchi, Cancer Chemotherapy Center, Osaka Medical College, Osaka, Japan.

Funding

This work was supported by Takeda Pharmaceutical Company Limited. Funding to pay the Open Access publication charges for this article was provided by Takeda Pharmaceutical Company.

Conflict of interest statement

N.B., K.S., Y.K., K.H., A.G., N.Y., K.M., T.H., T.Y. and A.O. are members of the Vectibix Appropriate Use/Safety Evaluation Committee. N.B. has received a consultancy fee from Takeda, speaker honoraria from Takeda, Taiho and Yakult, and research funding from Takeda, Bristol-Myers Squibb, Merck Serono and Chugai. K.S. has received consultancy fees from Taiho, Chugai, Takeda and Merck Serono, speaker honoraria from Taiho, Chugai, Yakult, Bristol-Myers Squibb, Merck Serono, Kyowa Hakko Kirin, Takeda, Kaken, Johnson & Johnson, Toray, Aska and Bayer, a manuscript fee from Chugai, and a donation from Taiho, Chugai, Yakult, Bristol-Myers Squibb, Merck Serono, Kyowa Hakko Kirin,
References

1. Siegel R, Desantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220–41.

2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.

3. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009;18:1688–94.

4. Colorectal Cancer Incidence and Mortality Worldwide in 2008. http://globocan.iarc.fr/factsheets/cancers/colorectal.asp#INCIDENCE1 (12 February 2013, date last accessed).

5. Wainberg ZA, Hecht JR. Panitumumab in colorectal cancer. Expert Rev Anticancer Ther 2007;7:967–73.

6. Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009;158:1–9.

7. Stintzing S, Heinemann V, Moosmann N, Hiddemann W, Jung A, Kirchner T. The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status. Dtsch Arztebl Int 2009;106:202–6.

8. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 2011;60:116–29.

9. Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G, Schwab G. From transgenic mice. Tumori 2007;110:980–8.

10. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Cancer 2007;110:980–8.

11. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626–34.

12. Weiner LM, Belledgeun AS, Crawford J, et al. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 2008;14:502–8.

13. Muro K, Yoshino T, Doi T, et al. A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 2009;39:321–6.

14. Siena S, Peeters M, Van Cutsem E, et al. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer 2007;97:1469–74.

15. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658–64.

16. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:6497–705.

17. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706–13.

18. New Drugs in Japan—Conditional Authorisation. http://www.pharmacosaurus.com/research_development/new_drugs_japan_conditional_authorisation.htm (31 October 2013, date last accessed).

19. Interpretation of Precautions for Use of Vectibix. http://www.vectibix-takeda.com/pdf/siyoujounotyuuikaisetsusho.pdf (24 April 2013, date last accessed).

20. Lacouture ME, Mitchell EP, Piperbi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin Treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:1351–7.

21. Van Cutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 2006;11:1010–7.

22. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913–21.

23. Ishiguro M, Watanabe T, Yamaguchi K, et al. A Japanese post-marketing surveillance of cetuximab (Erbitux) in patients with metastatic colorectal cancer. Jpn J Clin Oncol 2012;42:287–94.

24. Teijpar S, Pierssevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007;8:387–94.

25. Heun J, Holen K. Treatment with panitumumab after a severe infusion reaction with cetuximab. Cancer 2008;2:519–31.

26. Cartwright TH, Genthner R. Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer. Jpn J Clin Oncol 2012;42:287–94.

27. Saif MW, Peccherillo J, Potter V. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Cancer Chemother Pharmacol 2009;63:1017–22.

28. Brugger W. Successful treatment with the fully human antibody panitumumab after a severe infusion reaction with cetuximab. Tumori 2010;96:473–7.

29. Saif MW, Kaley K, Chu E, Copur MS. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clin Colorectal Cancer 2008;7:202–3.

30. Vectibix US Prescribing Information. http://www.vectibix.com/interactiveprescribinginfo/ipi/ipi.html (12 February 2013, date last accessed).

31. Saito Y, Gemma A. Current status of DILD in molecular targeted therapies. Int J Clin Oncol 2012;17:534–41.

32. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137–9.

33. Michel MC. Post-marketing studies can make important contributions to medical knowledge. BMJ 2012;345:e4740.